New Products In Brief
This article was originally published in The Gray Sheet
BioSTAR PFO closure device: NMT Medical launches its BioSTAR bioabsorbable atrial implant July 25 in Canada and Europe. The firm believes there may be a connection between closing septal heart defects, such as patent foramen ovale, with the device and prevention of embolic stroke and transient ischemic attack. NMT Medical estimates the market size in Canada and Europe for the indications to be 250,000 annually. AGA Medical's non-bioabsorbable Amplatzer PFO closure device is also available outside the United States. Both firms have U.S. trials underway to gain stroke prevention indications, and trials in the United States and internationally for prevention of migraine...
You may also be interested in...
NMT Medical is banking on strong market growth in Europe to counteract stagnant U.S. performance
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.